During the last session, 4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s traded shares were 0.74 million, with the beta value of the company hitting 2.79. At the end of the trading day, the stock’s price was $5.93, reflecting an intraday gain of 1.72% or $0.1. The 52-week high for the FDMT share is $36.25, that puts it down -511.3 from that peak though still a striking 11.97% gain since the share price plummeted to a 52-week low of $5.22. The company’s market capitalization is $274.13M, and the average intraday trading volume over the past 10 days was 1.42 million shares, and the average trade volume was 884.81K shares over the past three months.
4D Molecular Therapeutics Inc (FDMT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.64. FDMT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
4D Molecular Therapeutics Inc (FDMT) registered a 1.72% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.72% in intraday trading to $5.93, hitting a weekly high. The stock’s 5-day price performance is 2.07%, and it has moved by -16.24% in 30 days. Based on these gigs, the overall price performance for the year is -70.60%. The short interest in 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is 8.92 million shares and it means that shorts have 10.5 day(s) to cover.
The consensus price target of analysts on Wall Street is $39, which implies an increase of 84.79% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $36 and $40 respectively. As a result, FDMT is trading at a discount of -574.54% off the target high and -507.08% off the low.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
Statistics show that 4D Molecular Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. 4D Molecular Therapeutics Inc (FDMT) shares have gone down -71.96% during the last six months, with a year-to-date growth rate less than the industry average at -11.63% against 16.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -46.35%. While earnings are projected to return -13.00% in 2025.
FDMT Dividends
4D Molecular Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
4D Molecular Therapeutics Inc insiders own 3.91% of total outstanding shares while institutional holders control 114.53%, with the float percentage being 119.19%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 213.0 institutions own stock in it. As of 2024-06-30, the company held over 5.1 million shares (or 10.3471% of all shares), a total value of $107.01 million in shares.
The next largest institutional holding, with 4.9 million shares, is of BLACKROCK INC.’s that is approximately 9.9385% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $102.79 million.
